RCM
EW icon

Requisite Capital Management’s Edwards Lifesciences EW Stock Holding History

Requisite Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,188
Closed -$248K – 208
2025
Q3 		$248K Buy
+3,188
New +$249K 0.04% 280

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Requisite Capital Management's EW Position: Q4 2025 in Review

Requisite Capital Management sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 3,188 shares — an estimated $248K sold.

Requisite Capital Management first reported a position in EW in Q3 2025 and held it in 1 quarter. The position peaked at $248K in Q3 2025. 1,315 funds tracked by Wall St. Rank hold EW as of Q4 2025.

  • Requisite Capital Management reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
  • Requisite Capital Management sold 3,188 Edwards Lifesciences shares in Q4 2025, an estimated $248K.
  • Requisite Capital Management first reported a position in Edwards Lifesciences in Q3 2025 and held it in 1 quarter.
  • Requisite Capital Management's Edwards Lifesciences position peaked at $248K in Q3 2025.
  • 1,315 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Requisite Capital Management's 13F filing for Q4 2025, filed 5 Feb 2026.